Listening session with the US Food and Drug Administration, Lewy Body Dementia Association, and an expert panel
Abstract The regulatory path for drug approval is increasingly well defined. Drugs for the treatment of Alzheimer disease (AD) need to show statistically significant benefit over placebo with respect to cognitive and functional measures, with the Clinical Dementia Rating scale and Alzheimer's D...
Main Authors: | , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2023-01-01
|
Series: | Alzheimer’s & Dementia: Translational Research & Clinical Interventions |
Subjects: | |
Online Access: | https://doi.org/10.1002/trc2.12375 |